Thursday, September 17, 2020 3:20:05 AM
Vaxart’s application for a Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate has been cleared by the FDA.
Vaxart has announced that the US Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application for its Phase I clinical trial to evaluate its oral COVID-19 vaccine candidate, clearing the review.
The Phase I, open-label, dose-ranging study will be conducted in healthy adults ages 18 to 55 years old. The study’s primary objective is to examine the safety and reactogenicity of two doses of the vaccine. Secondary objectives include immunogenicity, duration of immune response and occurrence of symptomatic COVID-19.
“Our goal is to deliver the best, most elegant solution for conferring mass protection against COVID-19. Our oral tablet vaccine offers a much more attractive mode of administration than injectables and may confer superior protection against COVID-19 due to activation of mucosal immunity. Importantly, our room-temperature stable tablet is significantly easier and cheaper to store and distribute to the farthest corners of the US and the globe, as it does not require the very costly and complex refrigerated cold chain needed for injectable vaccines,” said Andrei Floroiu, Chief Executive Officer of Vaxart. “The IND clearance and the initiation of our Phase I clinical trial moves us a step closer to proving the superiority of our convenient oral COVID-19 solution in the clinic. We are thus excited to start enrolment for our Phase I this month.”
Dr Sean Tucker, Chief Scientific Officer of Vaxart, added: “In addition to our clinical programme progress, we have a hamster challenge study underway with our COVID-19 vaccine candidate to assess the potential contribution of inducing mucosal immunity to overall efficacy. We are also awaiting the results from a non-human primate study. Both hamsters and monkeys are susceptible to SARS-CoV-2 infection and these models may be capable of providing a deeper understanding of the immune responses and correlates of protection elicited by our oral vaccine candidate.”
A goal is a dreams deadline...what is your goal?
´¯`·.¸¸.·´¯`·.¸ ><((((((º>
`·.¸¸.·´¯`·.¸¸.·´¯`·.¸ ><((((º>
Recent VXRT News
- Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 04/30/2024 12:00:39 PM
- Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:13 PM
- Vaxart Provides Business Update and Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:01:00 PM
- U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb • IH Market News • 03/14/2024 11:41:01 AM
- Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:23:54 PM
- Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:10:21 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:16:04 PM
- Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/02/2024 09:49:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:14:20 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/19/2024 09:30:58 PM
- Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 01/19/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:18:45 PM
- Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management • GlobeNewswire Inc. • 01/16/2024 02:25:20 PM
- Vaxart, Inc. Announces Management Change • GlobeNewswire Inc. • 01/16/2024 02:22:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:19:43 PM
- Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 08:16:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 08:11:19 PM
- Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/02/2023 08:01:22 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM